

Jing Fu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4260476/publications.pdf>

Version: 2024-02-01

21
papers

619
citations

687363

13
h-index

794594

19
g-index

21
all docs

21
docs citations

21
times ranked

1076
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma. <i>Blood</i> , 2021, 137, 1754-1764.	1.4	7
2	Carbonic anhydrase 12 gene silencing reverses the sensitivity of paclitaxel in drug-resistant breast cancer cells. <i>Bioengineered</i> , 2021, 12, 9806-9818.	3.2	6
3	Cerebral Functional Manipulation of Repetitive Transcranial Magnetic Stimulation in Cognitive Impairment Patients After Stroke: An fMRI Study. <i>Frontiers in Neurology</i> , 2020, 11, 977.	2.4	32
4	IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation. <i>Blood Advances</i> , 2018, 2, 492-504.	5.2	15
5	Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation. <i>Haematologica</i> , 2018, 103, 1688-1697.	3.5	14
6	Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 711-719.	4.1	16
7	Multiple myeloma-derived MMP-13 mediates osteoclast fusion and osteolytic disease. <i>Journal of Clinical Investigation</i> , 2016, 126, 1759-1772.	8.2	54
8	Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization. <i>Leukemia</i> , 2013, 27, 1407-1411.	7.2	17
9	Inducible Silencing Of eIF4E Using a Tet-On System Results In Myeloma Growth In Vivo That Correlates With eIF4E Expression. <i>Blood</i> , 2013, 122, 3164-3164.	1.4	0
10	Knockdown Of Matrix Metalloproteinase 13 (MMP13) In 5TGM1 Multiple Myeloma Cells Inhibits Development Of Lytic Bone Lesions In Vivo. <i>Blood</i> , 2013, 122, 879-879.	1.4	0
11	Proteomic screen reveals Fbw7 as a modulator of the NF- κ B pathway. <i>Nature Communications</i> , 2012, 3, 976.	12.8	82
12	PDLIM2 restricts Th1 and Th17 differentiation and prevents autoimmune disease. <i>Cell and Bioscience</i> , 2012, 2, 23.	4.8	30
13	The tumor suppressor gene WWOX links the canonical and noncanonical NF- κ B pathways in HTLV-I Tax-mediated tumorigenesis. <i>Blood</i> , 2011, 117, 1652-1661.	1.4	67
14	Coordination of the canonical and noncanonical IKK/NF- κ B signaling pathways in HTLV-I Tax-mediated tumorigenesis. <i>Retrovirology</i> , 2011, 8, .	2.0	2
15	NF- κ B and cancer: a paradigm of Yin-Yang. <i>American Journal of Cancer Research</i> , 2011, 1, 192-221.	1.4	45
16	Molecular determinants of PDLIM2 in suppressing HTLV-I Tax-mediated tumorigenesis. <i>Oncogene</i> , 2010, 29, 6499-6507.	5.9	35
17	Epigenetic Repression of PDZ-LIM Domain-containing Protein 2. <i>Journal of Biological Chemistry</i> , 2010, 285, 11786-11792.	3.4	53
18	DNA Methylation-Dependent Repression of PDZ-LIM Domain-Containing Protein 2 in Colon Cancer and Its Role as a Potential Therapeutic Target. <i>Cancer Research</i> , 2010, 70, 1766-1772.	0.9	45

#	ARTICLE	IF	CITATIONS
19	PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation. <i>Blood</i> , 2009, 113, 4370-4380.	1.4	75
20	Inhibition of Inflammation by a p38 MAP Kinase Targeted Cell Permeable Peptide. <i>Medicinal Chemistry</i> , 2008, 4, 597-604.	1.5	10
21	Nuclear protein NP60 regulates p38 MAPK activity. <i>Journal of Cell Science</i> , 2006, 119, 115-123.	2.0	14